Psyence Biomedical Ltd.
PBM
$0.5171
-$0.0162-3.04%
NASDAQ
| 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | 09/30/2023 | |
|---|---|---|---|---|---|
| Net Income | 284.30% | 284.30% | -1,835.90% | -1,834.17% | -139.83% |
| Total Depreciation and Amortization | -- | -- | -- | -- | -- |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | -13,151.14% | -13,151.14% | 62,944.39% | 62,945.66% | -158.09% |
| Change in Net Operating Assets | 248.31% | 248.31% | -185.16% | -185.25% | 30.88% |
| Cash from Operations | 4.56% | 4.56% | -30.73% | -26.88% | -179.32% |
| Capital Expenditure | -- | -- | -- | -- | -- |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -- | -- | -- | -- |
| Cash from Investing | -- | -- | -- | -- | -- |
| Total Debt Issued | 39.86% | 39.86% | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | -- | -- | -- | -- | -- |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -106.62% | -106.79% | 110.78% |
| Cash from Financing | 216.69% | 216.69% | -30.72% | -31.71% | 183.73% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 264.57% | 264.57% | -88.56% | -86.91% | 54.31% |